J&J and Janssen Biotech Win Summary Judgment on Patent Acquisition Case
What happened
A Virginia court granted summary judgment to Johnson & Johnson and Janssen Biotech regarding antitrust claims brought by CareFirst. The court found insufficient evidence that Johnson & Johnson intended to use the acquired Momenta Pharmaceuticals manufacturing patents to exclude competitors. CareFirst has appealed the decision.
From mondaq.com
Why it matters
The ruling addresses claims that Johnson & Johnson violated Section 2 of the Sherman Act through its patent acquisition. This decision clears a major legal challenge related to the company's competitive practices in the pharmaceutical market.
Protagonist Therapeutics co-discovered ICOTYDE with Johnson & Johnson and subsequently licensed the technology to Janssen Biotech.
From mondaq.com
Who's involved
- Johnson & JohnsonAcquired Momenta Pharmaceuticals manufacturing patents subject to the antitrust claims.
- Janssen BiotechJointly won summary judgment in the Virginia court regarding the patent acquisition.
- companyFiled antitrust claims against the acquisition of the Momenta Pharmaceuticals patents.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Johnson & JohnsonSpeculative
Johnson & Johnson might reduce legal costs and regulatory uncertainty associated with the challenged acquisition.
Keep exploring
The entities involved
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
-
Janssen Biotech
Biotechnology company
Nothing else this week.